← Back to Search

Axitinib for Kidney Cancer

Phase 2

Waitlist Available

Led By Christopher Wood, MD

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from randomization until death or up to 10 years

Awards & highlights

Study Summary

This trial will study whether axitinib can help control kidney cancer, as well as the drug's safety.

Eligible Conditions

Kidney Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from randomization until death or up to 10 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from randomization until death or up to 10 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and from randomization until death or up to 10 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Objective Response Rate

Secondary outcome measures

Disease-Free Survival

Overall Survival

Side effects data

From 2019 Phase 2 trial • 13 Patients • NCT02129647

30%

Mucositis

10%

Fatigue

10%

Rash

10%

nausea

100%

80%

60%

40%

20%

Study treatment Arm

Axitinib

Trial Design

1Treatment groups

Experimental Treatment

Group I: AxitinibExperimental Treatment1 Intervention

Axitinib Starting dose: 5 mg by mouth twice each day for 12 weeks.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Axitinib

2020

Completed Phase 2

~3050

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

PfizerIndustry Sponsor

4,567 Previous Clinical Trials

10,911,835 Total Patients Enrolled

M.D. Anderson Cancer CenterLead Sponsor

2,967 Previous Clinical Trials

1,804,763 Total Patients Enrolled

Christopher Wood, MDPrincipal InvestigatorM.D. Anderson Cancer Center

Media Library

Axitinib Clinical Trial Eligibility Overview. Trial Name: NCT01263769 — Phase 2

Kidney Cancer Research Study Groups: Axitinib

Kidney Cancer Clinical Trial 2023: Axitinib Highlights & Side Effects. Trial Name: NCT01263769 — Phase 2

Axitinib 2023 Treatment Timeline for Medical Study. Trial Name: NCT01263769 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How does Axitinib compare to similar treatments in terms of risk?

"With data suggesting Axitinib's safety but not its efficacy, it is given a rating of 2."

Answered by AI

Is this clinical trial unique in its design and scope?

"Axitinib has been subject to a decade of scientific scrutiny, beginning with the Pfizer-sponsored study in 2011 involving 39 patients. Following this preliminary research and approval at Phase 2 level, Axitinib is now under investigation by 48 separate clinical trials across 30 nations worldwide."

Answered by AI

Are there any precedents of Axitinib being used in clinical research?

"At the present moment, 48 clinical trials concerning Axitinib are underway. Of these studies, 4 have reached Phase 3 of development. Although Houston is leading the way in this investigational research with numerous sites enrolled in such initiatives, there are 1038 other locations around the world that host such trials as well."

Answered by AI

How many individuals are taking part in this clinical research project?

"This clinical trial has ceased participant recruitment. It was initially posted on February 1st 2011 but its last update occurred on September 2nd 2022. If you are in search of other studies, presently there are 2641 trials for renal cancer and 48 trials for Axitinib seeking participants."

Answered by AI

Are there any vacancies available to join this experiment?

"Unfortunately, this medical trial has closed recruitment. It was published on February 1st 2011 and the last update occurred September 2nd 2022. If you are in search of other clinical research opportunities, 2641 studies involving renal cancers and 48 trials using Axitinib are currently searching for participants."

Answered by AI

Recent research and studies

European UrologyJournal

Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

Karam, Jose A., Catherine E. Devine, Diana L. Urbauer, Marisa Lozano, Tapati Maity, Kamran Ahrar, Pheroze Tamboli, Nizar M. Tannir, and Christopher G. Wood. 2014. “Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma”. European Urology. Elsevier BV. doi:10.1016/j.eururo.2014.01.035.

clinicaltrials.govStudy

Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)

2011. "Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01263769.